Drug intelligence / Profile preview

r9-Bor65-75

Development stage: Preclinical
Modality: Peptides
Administration: Intratumoral

Overview

r9-Bor65-75 is a synthetic peptide drug consisting of the cell-penetrating nona-d-arginine (r9) peptide conjugated to a borealin-derived peptide segment (Bor65-75). This conjugate was designed to target survivin, a protein highly expressed in most cancer cells but rarely in normal adult tissues. r9-Bor65-75 binds survivin with high affinity, inhibits the proliferation of cancer cells by inducing apoptosis, and shows significant antitumor activity in mouse xenograft models of pancreatic cancer. It is under preclinical investigation as a targeted anticancer therapeutic, with applications in both cancer imaging and therapy targeting survivin-positive tumors[1][2][3][4].

Other names: r9-Bor65-75r-9-Bor65-75r 9-Bor65-75

Targets

BIRC5 (Survivin)

Beyond the preview

Go deeper on r9-Bor65-75.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on r9-Bor65-75.

Explore the full profile